Number of Shares] THESEUS PHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • September 30th, 2021 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Form of Indemnification AgreementIndemnification Agreement • September 30th, 2021 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is made as of [•], 2021 by and between Theseus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [•] (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement.
THESEUS PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • November 3rd, 2022 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Theseus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
CONSULTING AGREEMENTConsulting Agreement • December 4th, 2023 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
THIS CONSULTING AGREEMENT (the “Agreement”), dated as of December 7, 2023 (the “Effective Date”), is between Theseus Pharmaceuticals, Inc., a Delaware corporation with a place of business at 314 Main Street, Suite 04-200, Cambridge, MA 02142, USA (“Company”) and David Kerstein, an individual having an address at 1 James Millen Rd., North Reading, MA 01864-2985 (“Consultant”). Consultant and Company (each a “Party”; collectively, the “Parties”) agree as follows:
AGREEMENT AND PLAN OF MERGER DATED AS OF DECEMBER 22, 2023 AMONG CONCENTRA BIOSCIENCES, LLC, CONCENTRA MERGER SUB II, INC. AND THESEUS PHARMACEUTICALS, INC.Merger Agreement • December 22nd, 2023 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●](this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Purchaser”), [●], a [●], as Rights Agent (as defined herein), and [●], solely in its capacity as the initial representative, agent and attorney in-fact of the Holders (the “Representative”).
December 7, 2023 Via Electronic Mail Tim ClacksonSeparation and Release Agreement • December 4th, 2023 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
As discussed, your employment with Theseus Pharmaceuticals, Inc. (the “Company”) will terminate on December 7, 2023. A copy of your Separation and Release Agreement is enclosed with this letter.
VIA ELECTRONIC MAIL William Shakespeare wcshake@gmail.com Re: Separation and Release Agreement Dear Bill: The purpose of this Separation and Release Agreement (the “Agreement”) is to confirm the terms regarding your separation of employment from...Separation and Release Agreement • November 13th, 2023 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations
LEASE AGREEMENT 314 MAIN STREET CAMBRIDGE, MASSACHUSETTS LEASE SUMMARY SHEETLease Agreement • September 30th, 2021 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
THIS INDENTURE OF LEASE (this “Lease”) is hereby made and entered into on the Execution Date by and between Landlord and Tenant.
